10/15/20 Update: Stryker entered a definitive agreement with Colfax Corporate / DJO Global for the divestiture of Stryker’s STAR total ankle replacement line and related products as well as finger joint replacement products.
In an amendment to its tender offer to purchase Wright Medical, Stryker proposed DJO Global as a buyer for its Scandinavian Total Ankle Replacement (STAR) line as well as certain finger joint replacement assets. The potential for anti-trust regulatory issues immediately emerged after Stryker announced its intent to acquire Wright Medical, given the considerable overlap between the lower extremity portfolios of the two companies.
The U.K.’s Competition and Markets Authority (CMA) announced at the end of June 2020 that Stryker’s acquisition of Wright Medical would result in a substantial lessening of competition (SLC) in U.K. total ankle replacement markets. However, per a recent announcement, the CMA accepted Stryker’s proposed divestment to DJO as a satisfactory resolution to the SLC issue.
Analysts from Jefferies estimated the worth of the STAR product line between $20 million and $30 million. Per ORTHOWORLD estimates, DJO’s extremity joint replacement business generated $190 million in 2019 through shoulder and elbow products. That segment declined -16.4% in the first half of 2020 due to COVID-19. The inclusion of STAR would meaningfully expand DJO’s portfolio and geographic footprint.
10/15/20 Update: Stryker entered a definitive agreement with Colfax Corporate / DJO Global for the divestiture of Stryker's STAR total ankle replacement line and related products as well as finger joint replacement products.
In an amendment to its tender offer to purchase Wright Medical, Stryker proposed DJO Global as a buyer for its...
10/15/20 Update: Stryker entered a definitive agreement with Colfax Corporate / DJO Global for the divestiture of Stryker’s STAR total ankle replacement line and related products as well as finger joint replacement products.
In an amendment to its tender offer to purchase Wright Medical, Stryker proposed DJO Global as a buyer for its Scandinavian Total Ankle Replacement (STAR) line as well as certain finger joint replacement assets. The potential for anti-trust regulatory issues immediately emerged after Stryker announced its intent to acquire Wright Medical, given the considerable overlap between the lower extremity portfolios of the two companies.
The U.K.’s Competition and Markets Authority (CMA) announced at the end of June 2020 that Stryker’s acquisition of Wright Medical would result in a substantial lessening of competition (SLC) in U.K. total ankle replacement markets. However, per a recent announcement, the CMA accepted Stryker’s proposed divestment to DJO as a satisfactory resolution to the SLC issue.
Analysts from Jefferies estimated the worth of the STAR product line between $20 million and $30 million. Per ORTHOWORLD estimates, DJO’s extremity joint replacement business generated $190 million in 2019 through shoulder and elbow products. That segment declined -16.4% in the first half of 2020 due to COVID-19. The inclusion of STAR would meaningfully expand DJO’s portfolio and geographic footprint.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
